Each November, Lung Cancer Awareness Month serves as a national reminder of the impact lung cancer has on patients, families, and communities. It is also a time to highlight the growing need for better diagnostic and treatment options—especially for patients facing advanced or metastatic disease.
One serious and often under-recognized complication of metastatic cancers is leptomeningeal metastases (LM), a condition in which cancer cells spread to the lining of the brain and spinal cord. LM is most commonly associated with lung cancer, as well as melanoma, breast cancer, and gastrointestinal cancers.
Raising awareness of LM is essential, as early detection and evaluation can help patients access clinical trials or emerging therapies that may improve outcomes.
What Is Leptomeningeal Metastases (LM)?
Leptomeningeal metastases occur when cancer cells enter the cerebrospinal fluid (CSF) and spread across the central nervous system (CNS). Symptoms can be varied and may include headaches, neurological changes, balance issues, or cognitive changes—making LM challenging to diagnose and treat with traditional therapies.
Because LM is more common in patients with metastatic lung cancer than many people realize, public education during Lung Cancer Awareness Month is especially important.
How Plus Therapeutics Is Working to Improve LM Treatment
Plus Therapeutics is developing innovative radiotherapeutic approaches to help address the unmet needs of patients with LM. The Company’s ongoing ReSPECT-LM clinical trial is designed to evaluate REYOBIQ™, an investigational radiopharmaceutical engineered for targeted delivery into the cerebrospinal fluid.
This treatment approach is intended to deliver therapeutic radiation directly to LM tumor cells with the goal of improving disease control while minimizing systemic side effects.
Patients diagnosed with LM—or caregivers supporting someone with LM—may wish to explore whether participation in the ReSPECT-LM trial could be an option.
Learn More or Check Eligibility
To see full study details or determine whether you or someone you know may qualify, visit:
www.respect-trials.com/lm
Sharing this information could help patients gain access to investigational therapies not available through standard treatment pathways.
Working Together to Support Lung Cancer Patients
During Lung Cancer Awareness Month, organizations like the Cancer Prevention and Research Institute of Texas, LUNGevity Foundation, and LiveLung continue to advocate for earlier detection, better support resources, and expanded research efforts.
Plus Therapeutics remains committed to advancing science that can meaningfully benefit patients with CNS complications of cancer, including leptomeningeal metastases.
Recent Comments